Exicure (NASDAQ:XCUR) and Creative Medical Technology (NASDAQ:CELZ) Head to Head Comparison

Exicure (NASDAQ:XCUR) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Valuation and Earnings

This table compares Exicure and Creative Medical Technology”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500,000.00	13.23	-$4.95 million	($1.32)	-0.77
Creative Medical Technology	$10,000.00	489.24	-$5.99 million	($2.07)	-0.36

Exicure has higher revenue and earnings than Creative Medical Technology. Exicure is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Exicure and Creative Medical Technology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1	0	0	0	1.00
Creative Medical Technology	1	0	1	0	2.00

Insider & Institutional Ownership

42.8% of Exicure shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 52.8% of Exicure shares are owned by insiders. Comparatively, 1.0% of Creative Medical Technology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Exicure and Creative Medical Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-237.91%	-61.98%
Creative Medical Technology	N/A	-86.52%	-81.96%

Volatility & Risk

Exicure has a beta of 3.64, suggesting that its share price is 264% more volatile than the S&P 500. Comparatively, Creative Medical Technology has a beta of 2.06, suggesting that its share price is 106% more volatile than the S&P 500.

Summary

Exicure beats Creative Medical Technology on 7 of the 11 factors compared between the two stocks.

About Exicure

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.